Pfizer (NYSE:PFE) Stock Price Up 2.6% After Strong Earnings

Posted by Stanley Muller on Nov 4th, 2026

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) rose 2.6% on Wednesday after the company announced better than expected quarterly earnings. The company traded as high as $30.90 and last traded at $30.7940. 46,682,176 shares were traded during mid-day trading, an increase of 17% from the average daily volume of 39,771,121 shares. The stock had previously closed at $30.00.

The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.13. The firm had revenue of $16.58 billion for the quarter, compared to analyst estimates of $15.85 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. Pfizer’s quarterly revenue was down .4% on a year-over-year basis. During the same period last year, the firm posted $0.87 EPS.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 5.6%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer beat third-quarter estimates, reporting adjusted EPS of $0.87 and revenue of $16.58 billion. It raised 2026 guidance to $62–$64 billion in revenue and $2.95–$3.05 in adjusted EPS. Article: Pfizer: 3 Key Takeaways for Long-Term Investors
Positive Sentiment: Growth is increasingly coming from beyond COVID: non-COVID products grew 7% operationally, while launched and acquired products grew 32%. Eliquis, Padcev and other newer medicines helped support results, strengthening the case that Pfizer’s portfolio can offset pandemic-product weakness. Article: Non-COVID Portfolio Steps Up
Positive Sentiment: Management is also pursuing growth in obesity medicines, with CEO Albert Bourla saying Pfizer aims to bring its past commercial experience to the weight-loss market. That opportunity could add longer-term upside, though it depends on pipeline and development progress. Article: Pfizer CEO Bourla Bets the Viagra Playbook Can Crack the Obesity Market
Neutral Sentiment: Pfizer appointed company veteran Cecile Guegan permanent CFO after she served as interim CFO. The appointment provides continuity, but the announcement itself offers limited immediate evidence of a change in financial performance. Article: Pfizer Appoints Cecile Guegan as Chief Financial Officer
Negative Sentiment: Quarterly revenue was nearly flat year over year as Comirnaty and Paxlovid sales declined sharply. This highlights the continuing challenge of replacing pandemic-era revenue and leaves Pfizer reliant on sustained growth from newer products. Article: Pfizer Q3 Revenue and Product Growth
Negative Sentiment: Analyst views remain restrained: RBC raised its target to $28 but kept a “sector perform” rating, and J.P. Morgan assigned a “Hold.” RBC’s target is below the cited $30.75 share price, signaling limited upside in its assessment. Article: RBC Raises Pfizer Price Target

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on PFE shares. Citigroup boosted their price target on shares of Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a research note on Wednesday. Royal Bank Of Canada raised their price objective on shares of Pfizer from $25.00 to $28.00 and gave the company a “sector perform” rating in a research report on Wednesday. HSBC lifted their price objective on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, September 10th. Bank of America dropped their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Finally, JPMorgan Chase & Co. increased their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Five equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus price target of $29.00.

View Our Latest Stock Report on PFE

Hedge Funds Weigh In On Pfizer

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. TOWER TRUST & INVESTMENT Co lifted its position in shares of Pfizer by 1.9% during the 3rd quarter. TOWER TRUST & INVESTMENT Co now owns 19,322 shares of the biopharmaceutical company’s stock valued at $551,000 after acquiring an additional 357 shares during the period. Angeles Wealth Management LLC boosted its stake in shares of Pfizer by 2.2% during the 2nd quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company’s stock worth $410,000 after acquiring an additional 358 shares in the last quarter. Manchester Financial Inc. boosted its stake in shares of Pfizer by 2.9% during the 2nd quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 365 shares in the last quarter. Signature Equity Partners LLC grew its holdings in shares of Pfizer by 22.9% in the 3rd quarter. Signature Equity Partners LLC now owns 2,067 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 385 shares during the period. Finally, Delta Financial Advisors LLC grew its holdings in shares of Pfizer by 1.6% in the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock worth $709,000 after acquiring an additional 398 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 2.6%

The stock has a market capitalization of $175.52 billion, a PE ratio of 40.52, a P/E/G ratio of 2.08 and a beta of 0.31. The firm has a 50 day moving average of $28.64 and a two-hundred day moving average of $26.84. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

About Pfizer

(Get Free Report)

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.